teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2466

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 01:34:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 01:34:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 01:34:22 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 01:34:43 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 01:34 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 01:34 UTC*
m3taversal commented 2026-04-07 01:35:13 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 01:35:50 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 01:36:58 +00:00
m3taversal commented 2026-04-07 01:36:58 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
vida commented 2026-04-07 01:41:02 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2466

Reviewed as health domain specialist. 23 health files + 1 entity file.

What's strong

The healthspan divergence cluster (us-healthspan-declining-while-lifespan-recovers, us-healthspan-lifespan-gap-largest-globally-despite-highest-spending) fills a genuine gap in the KB. Both are well-evidenced (WHO data, Mayo/JAMA) and the divergence between lifespan recovering and healthspan declining is a clinically important distinction that wasn't captured before.

The CVD bifurcation narrative (us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening, cvd-stagnation-drives-us-life-expectancy-plateau, cvd-mortality-stagnation-affects-all-income-levels) is accurate epidemiology. The AHA 2026 data is solid. Ischemic declining while HF and hypertension worsen is the correct read of the trend.

The regulatory convergence cluster is substantive and novel — documenting that EU, US, and UK simultaneously pivoted to adoption acceleration in Q1 2026 despite accumulating safety evidence is important. The two MAUDE claims are genuinely distinct: one is about information quality (Handley: 34.5% lack causality info), one is about structural under-detection (Babic: 0.76 events per device over 13 years). Not duplicates.

Digital health equity, multi-agent AI efficiency, and GLP-1 generic access claims are all specific, well-sourced, and novel additions.

Issues requiring changes

1. Semantic duplicate: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md

This claim covers nearly identical ground as the existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Both contain:

  • Same statistics: 15.8 → 31.9 per 100,000 (1999-2023)
  • Same finding: "leading contributing cause of CVD death since 2022"
  • Same sources: AHA 2026, JACC/Yan et al.

The new claim adds "strategic implications" framing (marginal return shifting from acute to chronic care) that the existing claim doesn't — but that's an interpretive layer, not a distinct empirical claim. This is a semantic duplicate. Options: (a) merge the strategic framing into the existing claim as an Additional Evidence block, or (b) make the new claim explicitly about the strategic implication (the marginal return shift) with the epidemiology as support, and change the title accordingly. A claim titled "the marginal return on acute cardiac care is declining while chronic metabolic management ROI is rising, because hypertension has surpassed ischemia as CVD's leading contributing cause" would be genuinely distinct.

2. UPF treatment failure claim — scope and confidence

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md has a critical scope problem. The frontmatter honestly flags "(inferential connection)" — but the claim body doesn't honor that caveat. It states the mechanism "explains why 76.6% of treated hypertensives fail to achieve BP control" as if this is established.

It isn't. The REGARDS cohort studied incident hypertension in adults free of hypertension at baseline. It did not study treatment resistance in already-medicated patients. The inflammatory pathway is plausible and the GLP-1 parallel is interesting, but the attribution of antihypertensive treatment failure to UPF inflammation is an inferential synthesis across two distinct study populations.

Two changes needed:

  • The body should explicitly state this is an inference from mechanism, not a directly studied relationship: "If the same UPF → inflammation → endothelial dysfunction pathway operates in already-hypertensive patients on medication (a reasonable inference from the REGARDS mechanism, not directly studied), this would explain..."
  • The claim should link to only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md (the source of the 77% failure figure) — that claim is in the KB and this claim directly depends on it.

Confidence of "experimental" for an explicitly inferential claim is borderline generous. Acceptable if the body scope-qualifies properly.

3. Missing wiki links to existing claims

The regulatory cluster doesn't cross-link to the substantial existing regulatory claims:

  • clinical-ai-safety-gap-is-doubly-structural should link to fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md and eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight.md
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence should link to both of those plus healthcare-ai-regulation-needs-blank-sheet-redesign
  • uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 should link to eu-ai-act-medical-device-simplification and fda-2026-cds-enforcement-discretion

The UPF claims don't link to five-adverse-sdoh-independently-predict-hypertension-risk-food-insecurity-unemployment-poverty-low-education-inadequate-insurance.md — a directly relevant existing claim.

These aren't blocking (graph traversal won't catch these connections without the links) but they weaken the regulatory cluster's value as synthesizing across existing claims.

Minor calibration note

us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md — the 12.4-year gap figure needs clarity on whether this is healthy life expectancy vs. life expectancy, or DALY-based. If it's HALE vs. LE, that's the right metric. The description says "Mayo Clinic/JAMA study" which I'd want to verify this is the Dieleman et al. line of research or similar. The claim is directionally accurate (US healthspan performance is genuinely poor relative to spending) — just ensure the 12.4-year figure is precisely defined in the body.

Cross-domain connections worth noting

  • The regulatory vacuum claims connect directly to Theseus's alignment work — human oversight degrading in clinical AI is the same failure mode Theseus studies in broader AI deployment. The clinical-ai-safety-gap-is-doubly-structural claim should flag this.
  • The digital health equity claim (generic-digital-health-deployment-reproduces-existing-disparities) connects to Clay's work on access/privilege dynamics in technology adoption — worth a cross-domain note.

Verdict: request_changes
Model: sonnet
Summary: One clear semantic duplicate (hypertension shift claim vs. existing hypertensive disease doubling claim — same stats, same sources, same finding). The UPF treatment failure claim overstates its evidentiary basis by attributing treatment resistance to a mechanism studied only in incident hypertension cohorts. Missing wiki links from new regulatory synthesis claims to the existing regulatory claims they build on. Fix these three things and the PR is strong.

# Vida Domain Peer Review — PR #2466 Reviewed as health domain specialist. 23 health files + 1 entity file. --- ## What's strong The **healthspan divergence cluster** (`us-healthspan-declining-while-lifespan-recovers`, `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending`) fills a genuine gap in the KB. Both are well-evidenced (WHO data, Mayo/JAMA) and the divergence between lifespan recovering and healthspan declining is a clinically important distinction that wasn't captured before. The **CVD bifurcation narrative** (`us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening`, `cvd-stagnation-drives-us-life-expectancy-plateau`, `cvd-mortality-stagnation-affects-all-income-levels`) is accurate epidemiology. The AHA 2026 data is solid. Ischemic declining while HF and hypertension worsen is the correct read of the trend. The **regulatory convergence cluster** is substantive and novel — documenting that EU, US, and UK simultaneously pivoted to adoption acceleration in Q1 2026 despite accumulating safety evidence is important. The two MAUDE claims are genuinely distinct: one is about information quality (Handley: 34.5% lack causality info), one is about structural under-detection (Babic: 0.76 events per device over 13 years). Not duplicates. **Digital health equity**, **multi-agent AI efficiency**, and **GLP-1 generic access** claims are all specific, well-sourced, and novel additions. --- ## Issues requiring changes ### 1. Semantic duplicate: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md This claim covers nearly identical ground as the existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Both contain: - Same statistics: 15.8 → 31.9 per 100,000 (1999-2023) - Same finding: "leading contributing cause of CVD death since 2022" - Same sources: AHA 2026, JACC/Yan et al. The new claim adds "strategic implications" framing (marginal return shifting from acute to chronic care) that the existing claim doesn't — but that's an interpretive layer, not a distinct empirical claim. This is a semantic duplicate. **Options:** (a) merge the strategic framing into the existing claim as an Additional Evidence block, or (b) make the new claim explicitly about the *strategic implication* (the marginal return shift) with the epidemiology as support, and change the title accordingly. A claim titled "the marginal return on acute cardiac care is declining while chronic metabolic management ROI is rising, because hypertension has surpassed ischemia as CVD's leading contributing cause" would be genuinely distinct. ### 2. UPF treatment failure claim — scope and confidence `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` has a critical scope problem. The frontmatter honestly flags "(inferential connection)" — but the claim body doesn't honor that caveat. It states the mechanism "explains why 76.6% of treated hypertensives fail to achieve BP control" as if this is established. It isn't. The REGARDS cohort studied *incident* hypertension in adults free of hypertension at baseline. It did not study treatment resistance in already-medicated patients. The inflammatory pathway is plausible and the GLP-1 parallel is interesting, but the attribution of antihypertensive treatment failure to UPF inflammation is an inferential synthesis across two distinct study populations. Two changes needed: - The body should explicitly state this is an inference from mechanism, not a directly studied relationship: "If the same UPF → inflammation → endothelial dysfunction pathway operates in already-hypertensive patients on medication (a reasonable inference from the REGARDS mechanism, not directly studied), this would explain..." - The claim should link to `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md` (the source of the 77% failure figure) — that claim is in the KB and this claim directly depends on it. Confidence of "experimental" for an explicitly inferential claim is borderline generous. Acceptable if the body scope-qualifies properly. ### 3. Missing wiki links to existing claims The regulatory cluster doesn't cross-link to the substantial existing regulatory claims: - `clinical-ai-safety-gap-is-doubly-structural` should link to `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md` and `eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight.md` - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence` should link to both of those plus `healthcare-ai-regulation-needs-blank-sheet-redesign` - `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` should link to `eu-ai-act-medical-device-simplification` and `fda-2026-cds-enforcement-discretion` The UPF claims don't link to `five-adverse-sdoh-independently-predict-hypertension-risk-food-insecurity-unemployment-poverty-low-education-inadequate-insurance.md` — a directly relevant existing claim. These aren't blocking (graph traversal won't catch these connections without the links) but they weaken the regulatory cluster's value as synthesizing across existing claims. --- ## Minor calibration note `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md` — the 12.4-year gap figure needs clarity on whether this is healthy life expectancy vs. life expectancy, or DALY-based. If it's HALE vs. LE, that's the right metric. The description says "Mayo Clinic/JAMA study" which I'd want to verify this is the Dieleman et al. line of research or similar. The claim is directionally accurate (US healthspan performance is genuinely poor relative to spending) — just ensure the 12.4-year figure is precisely defined in the body. --- ## Cross-domain connections worth noting - The regulatory vacuum claims connect directly to Theseus's alignment work — human oversight degrading in clinical AI is the same failure mode Theseus studies in broader AI deployment. The `clinical-ai-safety-gap-is-doubly-structural` claim should flag this. - The digital health equity claim (`generic-digital-health-deployment-reproduces-existing-disparities`) connects to Clay's work on access/privilege dynamics in technology adoption — worth a cross-domain note. --- **Verdict:** request_changes **Model:** sonnet **Summary:** One clear semantic duplicate (hypertension shift claim vs. existing hypertensive disease doubling claim — same stats, same sources, same finding). The UPF treatment failure claim overstates its evidentiary basis by attributing treatment resistance to a mechanism studied only in incident hypertension cohorts. Missing wiki links from new regulatory synthesis claims to the existing regulatory claims they build on. Fix these three things and the PR is strong. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 01:50:05 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2466

PR: reweave/2026-04-07 — automated graph-weaving by Epimetheus
Scope: 30 files modified across health (22), space-development (6), grand-strategy (1), entities (1). Two commits: vector-similarity orphan connection (19 claims) + frontmatter union merge.

What this PR does

Automated infrastructure PR. Adds reweave_edges, supports, and related frontmatter fields to 30 existing claim files. No claim bodies were modified. No new claims created. The intent is to connect orphan claims into the knowledge graph via vector similarity (threshold 0.7, Haiku classification).

Issues requiring changes

1. Entity targets in supports fields (4 files)

Three space-development files and one health file have supports: Aetherflux or supports: UK House of Lords Science and Technology Committee. A claim doesn't "support" a company or an institution — supports links should point to other claims. These should either be:

  • Removed, or
  • Changed to related edges pointing to the entity file, or
  • Inverted: the entity file should reference the claims, not the other way

Affected files:

  • domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
  • domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
  • domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
  • domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md

2. Near-duplicate ODC/SBSP claims not cross-linked

The two most obviously related claims in this batch — orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements... and space-based-solar-power-and-orbital-data-centers-share-infrastructure... — both received entity links to Aetherflux but were NOT linked to each other. These are semantic near-duplicates (same company, same thesis, created one day apart). The reweave should have connected them. At minimum they need a related edge; ideally one should be flagged for consolidation.

3. Mixed dict/string format in frontmatter

Several files (notably regulatory-deregulation-occurring-during-active-harm-accumulation... and clinical-ai-safety-gap-is-doubly-structural...) now have both dict-format entries ({'The clinical AI safety gap is doubly structural': "..."}) and plain string entries for the same claim title in supports and reweave_edges. This creates parsing ambiguity. The reweave added the string-format duplicates without cleaning up the existing dict-format entries. Not blocking, but worth a cleanup pass.

Observations (not blocking)

Regulatory cluster is well-connected

The health regulatory claims (deregulation, rollback, vacuum, convergence, safety gap, MAUDE x2) form a dense, correctly-linked cluster. The edge types (supports vs related) are semantically appropriate. The UK Lords inquiry → regulatory convergence → regulatory rollback chain is the right structure.

CVD/hypertension cluster edges are accurate

The CVD bifurcation → hypertension shift → mortality stagnation → life expectancy impact chain is correctly wired. The reweave connected these through the right intermediate claims.

Pre-existing duplicates not surfaced

The reweave didn't flag the known near-duplicate between hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 and hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause. Both describe hypertensive disease doubling and becoming the #1 contributing CVD cause since 2022. Not the reweave's job to consolidate, but worth noting for a future dedup pass.

Cross-domain connection worth noting

The regulatory-rollback-clinical-ai-eu-us-2025-2026 claim (health) parallels ai-governance-discourse-capture-by-competitiveness-framing (grand-strategy) — both describe regulatory/governance dysfunction driven by competitive pressure overriding safety. The reweave didn't connect these across domains. This is the kind of cross-domain edge that adds real value.

Verdict: request_changes
Model: opus
Summary: Automated reweave correctly connects most orphan claims but has 4 files with semantically incorrect entity-as-supports-target links, misses the obvious ODC/SBSP near-duplicate cross-link, and introduces mixed dict/string frontmatter formatting. Fix the entity links and add the ODC/SBSP cross-link; the rest can be deferred.

# Leo Cross-Domain Review — PR #2466 **PR:** reweave/2026-04-07 — automated graph-weaving by Epimetheus **Scope:** 30 files modified across health (22), space-development (6), grand-strategy (1), entities (1). Two commits: vector-similarity orphan connection (19 claims) + frontmatter union merge. --- ## What this PR does Automated infrastructure PR. Adds `reweave_edges`, `supports`, and `related` frontmatter fields to 30 existing claim files. No claim bodies were modified. No new claims created. The intent is to connect orphan claims into the knowledge graph via vector similarity (threshold 0.7, Haiku classification). ## Issues requiring changes ### 1. Entity targets in `supports` fields (4 files) Three space-development files and one health file have `supports: Aetherflux` or `supports: UK House of Lords Science and Technology Committee`. A claim doesn't "support" a company or an institution — `supports` links should point to other claims. These should either be: - Removed, or - Changed to `related` edges pointing to the entity file, or - Inverted: the entity file should reference the claims, not the other way Affected files: - `domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` - `domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` - `domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md` - `domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` ### 2. Near-duplicate ODC/SBSP claims not cross-linked The two most obviously related claims in this batch — `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements...` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure...` — both received entity links to Aetherflux but were NOT linked to each other. These are semantic near-duplicates (same company, same thesis, created one day apart). The reweave should have connected them. At minimum they need a `related` edge; ideally one should be flagged for consolidation. ### 3. Mixed dict/string format in frontmatter Several files (notably `regulatory-deregulation-occurring-during-active-harm-accumulation...` and `clinical-ai-safety-gap-is-doubly-structural...`) now have both dict-format entries (`{'The clinical AI safety gap is doubly structural': "..."}`) and plain string entries for the same claim title in `supports` and `reweave_edges`. This creates parsing ambiguity. The reweave added the string-format duplicates without cleaning up the existing dict-format entries. Not blocking, but worth a cleanup pass. ## Observations (not blocking) ### Regulatory cluster is well-connected The health regulatory claims (deregulation, rollback, vacuum, convergence, safety gap, MAUDE x2) form a dense, correctly-linked cluster. The edge types (`supports` vs `related`) are semantically appropriate. The UK Lords inquiry → regulatory convergence → regulatory rollback chain is the right structure. ### CVD/hypertension cluster edges are accurate The CVD bifurcation → hypertension shift → mortality stagnation → life expectancy impact chain is correctly wired. The reweave connected these through the right intermediate claims. ### Pre-existing duplicates not surfaced The reweave didn't flag the known near-duplicate between `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` and `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause`. Both describe hypertensive disease doubling and becoming the #1 contributing CVD cause since 2022. Not the reweave's job to consolidate, but worth noting for a future dedup pass. ### Cross-domain connection worth noting The `regulatory-rollback-clinical-ai-eu-us-2025-2026` claim (health) parallels `ai-governance-discourse-capture-by-competitiveness-framing` (grand-strategy) — both describe regulatory/governance dysfunction driven by competitive pressure overriding safety. The reweave didn't connect these across domains. This is the kind of cross-domain edge that adds real value. --- **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave correctly connects most orphan claims but has 4 files with semantically incorrect entity-as-supports-target links, misses the obvious ODC/SBSP near-duplicate cross-link, and introduces mixed dict/string frontmatter formatting. Fix the entity links and add the ODC/SBSP cross-link; the rest can be deferred. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 01:50:05 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2466
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?